Triple Drug Therapy for Prion Infection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease (AD) are ineffective in modifying the progression or preventing the onset of the disease, with existing therapies only providing symptomatic improvement and failing to address the underlying pathology.
Innovation Solution
A combination therapy using tetracyclines as antibiotics to inhibit amyloid protein synthesis and sirolimus as an immunosuppressant to target the prion protein complex, addressing both systemic and central nervous system components of AD, by blocking transcription and protein synthesis, thereby disrupting the rogue prion protein complex.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used for Alzheimer's disease, then symptomatic improvement is achieved, but disease progression cannot be modified and underlying pathology is not addressed
Solution Approach 1:
The therapy is divided into three distinct pharmaceutical components, each targeting specific aspects of AD pathology: (1) a tetracycline antibiotic to inhibit amyloid protein synthesis, (2) sirolimus to suppress B-cell activity and prion protein complex, and (3) a statin to reduce cholesterol and inflammation. This segmentation allows simultaneous attack on multiple pathological mechanisms without interference between treatments.
Solution Approach 2:
The patent combines three medications with different mechanisms of action into a single therapeutic regimen. The tetracycline, sirolimus, and statin work synergistically to address both the amyloid protein deposition hypothesis and the prion protein complex theory, creating a comprehensive disease-modifying approach that conventional single-agent therapies cannot achieve.
2Adaptability or versatility
If multiple separate medications are used to address different AD pathologies, then comprehensive coverage is achieved, but treatment complexity and compliance difficulty increase
Solution Approach 1:
The patent merges three separate medications (tetracycline, sirolimus, and statin) into a single combined pharmaceutical composition. This consolidation maintains comprehensive coverage of multiple AD pathologies while simplifying the treatment regimen to a single daily dose, improving patient compliance and reducing the burden of managing multiple medications.
3Reliability
If existing antibiotics and immunosuppressants are used separately, then specific targets are addressed, but synergistic effect is not achieved
Solution Approach 1:
The patent combines a tetracycline antibiotic, sirolimus immunosuppressant, and statin into a single formulation. This merging creates synergistic therapeutic effects where the tetracycline inhibits amyloid protein synthesis, sirolimus suppresses B-cell activity and prion protein complex, and the statin reduces cholesterol and inflammation, achieving greater overall efficacy than any single agent could provide alone.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively halts further amyloid protein deposition, reduces neurotoxicity, and improves cognitive and daily functioning in AD patients, with noticeable effects in as little as 72 hours and sustained improvements over several months.
Implementation Method 1
tetracyclines as antibiotics to inhibit amyloid protein synthesis... by blocking transcription and protein synthesis
Implementation Method 2
sirolimus as an immunosuppressant to target the prion protein complex... disrupting the rogue prion protein complex
Data Source
Figure 1
Figure 2
Figure 3
AI summary
There are disclosed therapies and preventions of prion protein complex infections. The transcription of the amyloid precursor protein gene and PrP gene and the RNA transcript are the rate-limiting steps and are most susceptible for blockage and control of the process of amyloid protein formation and PrPsc formation. Thus, therapies and prevention regimes for prion protein complex infections interrupt this process at the level of DNA transcription to RNA, RNA transport to the mitochondrion for protein synthesis and deposition in the cerebral cortex neurons.